AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
inavolisib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| phosphatidylinositol 3-kinase inhibitors, antineoplastics | 5836 | 2060571-02-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Inavolisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. In vitro, inavolisib induced the degradation of mutated PI3K catalytic alpha subunit p110α (encoded by the PIK3CA gene), inhibited phosphorylation of the downstream target AKT, reduced cellular proliferation, and induced apoptosis in PIK3CA-mutated breast cancer cell lines. In vivo, inavolisib reduced tumor growth in PIK3CA-mutated, estrogen receptor-positive, breast cancer xenograft models.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 9 | mg | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 10, 2024 | FDA | Genentech (Roche) | |
| July 18, 2025 | EMA | Roche Registration GmbH |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperglycaemia | 291.45 | 57.18 | 67 | 535 | 50903 | 90576942 |
| Blood glucose increased | 115.30 | 57.18 | 37 | 565 | 95209 | 90532636 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperglycaemia | 107.62 | 55.27 | 30 | 386 | 85060 | 110503823 |
| Blood glucose increased | 74.12 | 55.27 | 25 | 391 | 132471 | 110456412 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01EM06 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Phosphatidylinositol-3-kinase (Pi3K) inhibitors |
| MeSH PA | D000081082 | Phosphoinositide-3 Kinase Inhibitors |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| FDA EPC | N0000175605 | Kinase Inhibitor |
| FDA MoA | N0000194130 | Phosphoinositide 3-Kinase alpha Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Locally advanced or metastatic breast cancer | indication | 254837009 | DOID:1612 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 3MG | ITOVEBI | GENENTECH INC | N219249 | Oct. 10, 2024 | RX | TABLET | ORAL | 8343955 | Sept. 27, 2030 | COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY |
| 9MG | ITOVEBI | GENENTECH INC | N219249 | Oct. 10, 2024 | RX | TABLET | ORAL | 8343955 | Sept. 27, 2030 | COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY |
| 3MG | ITOVEBI | GENENTECH INC | N219249 | Oct. 10, 2024 | RX | TABLET | ORAL | 11760753 | July 1, 2036 | COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY |
| 3MG | ITOVEBI | GENENTECH INC | N219249 | Oct. 10, 2024 | RX | TABLET | ORAL | 9650393 | July 1, 2036 | COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY |
| 9MG | ITOVEBI | GENENTECH INC | N219249 | Oct. 10, 2024 | RX | TABLET | ORAL | 11760753 | July 1, 2036 | COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY |
| 9MG | ITOVEBI | GENENTECH INC | N219249 | Oct. 10, 2024 | RX | TABLET | ORAL | 9650393 | July 1, 2036 | COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY |
| 3MG | ITOVEBI | GENENTECH INC | N219249 | Oct. 10, 2024 | RX | TABLET | ORAL | 12410189 | June 14, 2038 | COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY |
| 9MG | ITOVEBI | GENENTECH INC | N219249 | Oct. 10, 2024 | RX | TABLET | ORAL | 12410189 | June 14, 2038 | COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 3MG | ITOVEBI | GENENTECH INC | N219249 | Oct. 10, 2024 | RX | TABLET | ORAL | Oct. 10, 2029 | NEW CHEMICAL ENTITY |
| 9MG | ITOVEBI | GENENTECH INC | N219249 | Oct. 10, 2024 | RX | TABLET | ORAL | Oct. 10, 2029 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Kinase | INHIBITOR | IC50 | 10.42 | DRUG LABEL | DRUG LABEL | |||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Kinase | INHIBITOR | Ki | 7.74 | IUPHAR | ||||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Kinase | INHIBITOR | Ki | 7.91 | IUPHAR | ||||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Kinase | INHIBITOR | Ki | 7 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| MWF | PDB_CHEM_ID |
| CHEMBL4650215 | ChEMBL_ID |
| C000723546 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB15275 | DRUGBANK_ID |
| 4043515 | VANDF |
| C5446307 | UMLSCUI |
| CHEBI:758122 | CHEBI |
| 11204 | INN_ID |
| 124173720 | PUBCHEM_CID |
| 43338 | MMSL |
| d10228 | MMSL |
| 9636 | IUPHAR_LIGAND_ID |
| L4C1UY2NYH | UNII |
| 2695422 | RXNORM |
| 933451381000036107 | SNOMEDCT_US |
| D11942 | KEGG_DRUG |
| 019886 | NDDF |
| L4C1UY2NYH | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Itovebi | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-079 | TABLET, FILM COATED | 9 mg | ORAL | NDA | 31 sections |
| Itovebi | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-079 | TABLET, FILM COATED | 9 mg | ORAL | NDA | 31 sections |
| Itovebi | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-084 | TABLET, FILM COATED | 3 mg | ORAL | NDA | 31 sections |
| Itovebi | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-084 | TABLET, FILM COATED | 3 mg | ORAL | NDA | 31 sections |